CareDx (CDNA) Is Up 39.4% After Final Medicare Coverage Clarifies Transplant Test Reimbursement Limits

Simply Wall St.07-19

CareDx, Inc. recently secured a final Medicare Local Coverage Determination that confirms and aligns reimbursement for its AlloSure and AlloMap transplant surveillance tests in kidney, heart, and lung...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652125549?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-19 10:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652125549","market":"us","top_or_hot":-1,"title":"CareDx (CDNA) Is Up 39.4% After Final Medicare Coverage Clarifies Transplant Test Reimbursement Limits","media":"Simply Wall St.","content":"<div>\n<p>CareDx, Inc. recently secured a final Medicare Local Coverage Determination that confirms and aligns reimbursement for its AlloSure and AlloMap transplant surveillance tests in kidney, heart, and lung...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/caredx-cdna-is-up-394-after-final-medicare-coverage-clarifie\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CareDx (CDNA) Is Up 39.4% After Final Medicare Coverage Clarifies Transplant Test Reimbursement Limits</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCareDx (CDNA) Is Up 39.4% After Final Medicare Coverage Clarifies Transplant Test Reimbursement Limits\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-19 10:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/caredx-cdna-is-up-394-after-final-medicare-coverage-clarifie><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CareDx, Inc. recently secured a final Medicare Local Coverage Determination that confirms and aligns reimbursement for its AlloSure and AlloMap transplant surveillance tests in kidney, heart, and lung...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/caredx-cdna-is-up-394-after-final-medicare-coverage-clarifie\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CDNA","symbol_name":"CareDx","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/caredx-cdna-is-up-394-after-final-medicare-coverage-clarifie","article_id":"2652125549","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cdna/caredx/news/caredx-cdna-is-up-394-after-final-medicare-coverage-clarifie","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652125549","pubTimestamp":1784427788,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CareDx, Inc. recently secured a final Medicare Local Coverage Determination that confirms and aligns reimbursement for its AlloSure and AlloMap transplant surveillance tests in kidney, heart, and lung, including defined test frequencies for the critical first three years post-transplant.\nThis decision reduces reimbursement uncertainty and more closely matches actual clinical testing patterns, potentially giving CareDx clearer visibility into demand and test utilization across its transplant...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CDNA":"CareDx","BK4139":"生物科技"},"translate_title":"最终医疗保险覆盖范围明确移植测试报销限额后，CareDx (CDNA) 上涨 39.4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDNA":1.5},"content_text":"CareDx, Inc. recently secured a final Medicare Local Coverage Determination that confirms and aligns reimbursement for its AlloSure and AlloMap transplant surveillance tests in kidney, heart, and lung, including defined test frequencies for the critical first three years post-transplant. This decision reduces reimbursement uncertainty and more closely matches actual clinical testing patterns, potentially giving CareDx clearer visibility into demand and test utilization across its transplant portfolio. We’ll now examine how this finalized Medicare coverage framework, especially the clarified test frequency limits, influences CareDx’s broader investment narrative. Find 47 companies with promising cash flow potential yet trading below their fair value.AdvertisementCareDx Investment Narrative RecapTo own CareDx, you need to believe that transplant surveillance testing remains central to post-transplant care and that the company can sustain strong demand for AlloSure and HeartCare while managing reimbursement exposure. The finalized Medicare LCD reduces near term uncertainty on test coverage and frequency, which supports the key near term catalyst of stable US reimbursement. At the same time, it does not remove the broader risk that future payer or policy changes could still pressure pricing and volumes. Among recent announcements, the US$100,000,000 share repurchase authorization from April 2026 stands out here, because it sits against a backdrop of a share price that has already more than doubled year to date. For investors, that raises practical questions about how capital returns, ongoing buybacks, and the clarified Medicare coverage framework together influence CareDx’s financial flexibility and the balance between funding growth initiatives and returning cash to shareholders. Read the full narrative on CareDx (it's free!)CareDx's narrative projects $524.6 million revenue and $49.9 million earnings by 2029. This requires 8.3% yearly revenue growth and a $58.1 million earnings increase from -$8.2 million today.Uncover how CareDx's forecasts yield a $27.80 fair value, a 30% downside to its current price.Exploring Other PerspectivesCDNA 1-Year Stock Price Chart Yet while bullish analysts were assuming revenue of about US$559,000,000 and earnings of roughly US$66,700,000 by 2029, the unresolved risk around future Medicare pricing policies is something investors should be aware of...Explore 4 other fair value estimates on CareDx - why the stock might be worth 30% less than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your CareDx research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free CareDx research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CareDx's overall financial health at a glance.Contemplating Other Strategies?Opportunities like this don't last. These are today's most promising picks. Check them out now:AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Outshine the giants: these 16 early-stage AI stocks could fund your retirement.Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652125549","isCrawlerRequest":true}